Heterologous Hydrogenase Overproduction Systems for Biotechnology—An Overview

by Qin Fan, Peter Neubauer, Oliver Lenz, Matthias Gimpel
Published 2020-08-01

A membrane‐bound [NiFe]‐hydrogenase large subunit precursor whose C‐terminal extension is not essential for cofactor incorporation but guarantees optimal maturation

by Sven Hartmann, Stefan Frielingsdorf, Giorgio Caserta, Oliver Lenz
Published 2020-06-01

Catalytic properties of the isolated diaphorase fragment of the NAD-reducing [NiFe]-hydrogenase from Ralstonia eutropha.

by Lars Lauterbach, Zulkifli Idris, Kylie A Vincent, Oliver Lenz
Published 2011-01-01

Growth of the facultative chemolithoautotroph Ralstonia eutropha on organic waste materials: growth characteristics, redox regulation and hydrogenase activity

by Anna Poladyan, Syuzanna Blbulyan, Mayramik Sahakyan, Oliver Lenz, Armen Trchounian
Published 2019-11-01

An Unusual Presentation of Tumor Lysis Syndrome in a Patient with Advanced Gastric Adenocarcinoma: Case Report and Literature Review

by Danica Maria Vodopivec, Jose Enrique Rubio, Alessia Fornoni, Oliver Lenz
Published 2012-01-01

The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure

by Ovidio De Freitas, Oliver Lenz, Alessia Fornoni, Barry J Materson
Published 2006-06-01

Optimization of Culture Conditions for Oxygen-Tolerant Regulatory [NiFe]-Hydrogenase Production from <i>Ralstonia eutropha</i> H16 in <i>Escherichia coli</i>

by Qin Fan, Giorgio Caserta, Christian Lorent, Oliver Lenz, Peter Neubauer, Matthias Gimpel
Published 2021-05-01

A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection

by Fabien Zoulim, Christophe Moreno, Samuel S. Lee, Peter Buggisch, Andrzej Horban, Eric Lawitz, Chris Corbett, Oliver Lenz, Bart Fevery, Thierry Verbinnen, Umesh Shukla, Wolfgang Jessner
Published 2018-01-01

Orientation-Controlled Electrocatalytic Efficiency of an Adsorbed Oxygen-Tolerant Hydrogenase.

by Nina Heidary, Tillmann Utesch, Maximilian Zerball, Marius Horch, Diego Millo, Johannes Fritsch, Oliver Lenz, Regine von Klitzing, Peter Hildebrandt, Anna Fischer, Maria Andrea Mroginski, Ingo Zebger
Published 2015-01-01

Advancing the regulatory path on hepatitis B virus treatment and curative research: a stakeholders consultation

by Jonathan Liu, Pedro Goicochea, Timothy Block, Carol L. Brosgart, Eric F. Donaldson, Oliver Lenz, Seng Gee Lim, Ed G. Marins, Poonam Mishra, Marion G. Peters, Veronica Miller
Published 2017-01-01

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1).

by Tarik Asselah, Christophe Moreno, Christoph Sarrazin, Michael Gschwantler, Graham R Foster, Antonio Craxí, Peter Buggisch, Robert Ryan, Oliver Lenz, Jane Scott, Gino Van Dooren, Isabelle Lonjon-Domanec, Michael Schlag, Maria Buti
Published 2016-01-01

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate...

by Tarik Asselah, Christophe Moreno, Christoph Sarrazin, Michael Gschwantler, Graham R Foster, Antonio Craxí, Peter Buggisch, Faisal Sanai, Ceyhun Bicer, Oliver Lenz, Gino Van Dooren, Catherine Nalpas, Isabelle Lonjon-Domanec, Michael Schlag, Maria Buti
Published 2017-01-01

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study

by Edward J. Gane, Edwin DeJesus, Ewa Janczewska, Jacob George, Moises Diago, Mariliza Hendrique Da Silva, Henk Reesink, Igor Nikitin, Holger Hinrichsen, Stefan Bourgeois, Peter Ferenci, Umesh Shukla, Ronald Kalmeijer, Oliver Lenz, Bart Fevery, Chris Corbett, Maria Beumont, Wolfgang Jessner
Published 2017-06-01